Tuesday 13 October 2026
Export ENTX’s income statement to Excel — free account
Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.51
0.14
−5.28%
Follow ENTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.76 | 7.57 | 6.76 | 10.57 | |
Current Ratio |
8.98 | 7.93 | 6.94 | 10.83 | |
Net Debt/EBITDA |
4.05 | 3.38 | 4.90 | 5.11 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.47 | 0.88 | 0.61 | 0.78 | |
Capex/Depreciation |
(0.33) | 0.00 | (3.86) | (5.37) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.06) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.06) | (0.04) | (0.05) | |
Cash per Share |
0.37 | 0.25 | 0.32 | 0.35 | |
Shareholders Equity per Share |
0.14 | 0.22 | 0.28 | 0.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.14 | 0.22 | 0.28 | 0.32 | |
Free Cash Flow |
(3.47) | (3.09) | (1.86) | (2.54) | |
Working Capital |
16.79 | 10.92 | 13.10 | 15.44 | |
Capital Expenditures |
0.00 | — | (0.03) | (0.04) | |
Net Current Asset Value |
6.68 | 10.05 | 12.41 | 14.83 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.48 | 0.20 | 0.29 | 0.20 | |
Average Assets |
19.57 | 17.36 | 12.69 | 12.57 | |
Average Common Equity |
12.26 | 15.03 | 10.59 | 10.84 |
Columns are period end dates